TRIB
TRINITY BIOTECH PLC
$0.6800
+1.49%
$13.5M
No data for this timeframe.
Vol
Market Cap$13.5M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$32.1K
Inst. Activity1 buys / 1 sells
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. L2·CIK 0000888721·Prev Close $0.6700
Recent Activity
Jun 3, 2026
SEC
Trinity Biotech filed Post-Effective Amendment No. 1 to its F-1 registration statement, updating the prospectus to inclu
F-1/A — Impact 6/10
May 26, 2026
SEC
The SEC declared effective Trinity Biotech's F-3 shelf registration (File No. 333-295842) on May 22, 2026, enabling the
EFFECT — Impact 6/10
May 1, 2026
other
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
<p align="center">- Appointment supports revenue quality and profitability momentum as the Company a
Mar 23, 2026
Press
Trinity Biotech announced successful clinical validation of an enhanced version of its EpiCapture™ prostate cancer test,
Impact 7/10
Mar 4, 2026
SEC
Trinity Biotech PLC's Form F-1 registration statement has become effective, allowing the company to proceed with a propo
EFFECT — Impact 5/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEAR_EXIT
20,262 shares ($16.0K)
Inst.
BANK OF AMERICA CORP — DOUBLED
1,095 shares ($867.00)
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Latest Reports
BEARISH
F-1/A
6/10
Trinity Biotech filed Post-Effective Amendment No. 1 to its F-1 registration statement, updating the prospectus to inclu
Jun 3, 2026
BEARISH
EFFECT
6/10
The SEC declared effective Trinity Biotech's F-3 shelf registration (File No. 333-295842) on May 22, 2026, enabling the
May 26, 2026
BULLISH
Press
7/10
Trinity Biotech announced successful clinical validation of an enhanced version of its EpiCapture™ prostate cancer test,
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $16.0K | NEAR_EXIT |
| TWO SIGMA INVESTMENTS, LP | $14.8K | ADD |
| BANK OF AMERICA CORP | $867.00 | DOUBLED |
| MORGAN STANLEY | $459.00 | — |
| FMR LLC | $9.00 | — |
5 institutional holders with $32.1K total value (40,598 shares) as of 2025-Q4. Top holders: RENAISSANCE, TWO, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 20,262 | $16.0K | 49.9% | NEAR_EXIT -88.2% |
| 2 | TWO SIGMA INVESTMENTS, LP | 18,650 | $14.8K | 45.9% | ADD +59.1% |
| 3 | BANK OF AMERICA CORP /DE/ | 1,095 | $867.00 | 2.7% | DOUBLED +2637.5% |
| 4 | MORGAN STANLEY | 580 | $459.00 | 1.4% | — |
| 5 | FMR LLC | 11 | $9.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 171,362 | 20,262 | -88.2% | $16.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 40 | 1,095 | +2637.5% | $867.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 56,965 | 171,362 | +200.8% | $178.2K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 15,073 | 23,986 | +59.1% | $24.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 80 | 40 | -50.0% | $42.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 76,665 | 56,965 | -25.7% | $37.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 40 | 80 | +100.0% | $52.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 189,053 | 76,665 | -59.4% | $43.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 68,239 | — | $38.9K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 14,151 | 0 | -100.0% | $0.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 6.3/10.
BEARISH
F-1/A
6/10
Trinity Biotech filed Post-Effective Amendment No. 1 to its F-1 registration statement, updating the
Jun 3, 2026
BEARISH
EFFECT
6/10
The SEC declared effective Trinity Biotech's F-3 shelf registration (File No. 333-295842) on May 22,
May 26, 2026
NEUTRAL
EFFECT
5/10
Trinity Biotech PLC's Form F-1 registration statement has become effective, allowing the company to
Mar 4, 2026
BEARISH
F-1
8/10
Trinity Biotech is registering up to 35.3 million American Depositary Shares (ADSs) for resale by a
Feb 25, 2026
Historical analyst distribution: 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2025-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jan 1, 2023 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Dec 1, 2022 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Nov 1, 2022 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Oct 1, 2022 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 1, 2026
other
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
<p align="center">- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base <br></p>
Apr 27, 2026
earnings_calendar
TRIB Q4 2025 Earnings Before Market Open — 2026-04-27
Apr 15, 2026
earnings_calendar
TRIB Q4 2025 Earnings Before Market Open — 2026-04-15
Apr 6, 2026
earnings_calendar
TRIB Q4 2025 Earnings Before Market Open — 2026-04-06
Apr 3, 2026
earnings_calendar
TRIB Q4 2025 Earnings Before Market Open — 2026-04-03
Mar 23, 2026
fda
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
<p align="justify">DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a global diagnostics company, today a
Mar 10, 2026
other
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
<p align="center"><em> - Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization</em> </p>
Mar 10, 2026
other
Trinity Biotech Provides Business and Trading Update
<p align="justify">DUBLIN, March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused o